Hermetica Superfood Encyclopedia
The Short Answer
Frankincense (Boswellia sacra) exerts anti-inflammatory effects primarily through acetyl-11-keto-β-boswellic acid (AKBA), a pentacyclic triterpenic acid that selectively inhibits 5-lipoxygenase (5-LOX), suppressing pro-inflammatory leukotriene biosynthesis at concentrations of 1–10 μM. Most clinical evidence derives from closely related Boswellia serrata, where standardized extracts at 900 mg/day have demonstrated therapeutic effects in inflammatory conditions, though species-specific trials for B. sacra remain limited.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary Keywordfrankincense benefits
Frankincense — botanical close-up
Health Benefits
**Anti-inflammatory Activity**
AKBA and other boswellic acids inhibit 5-lipoxygenase (5-LOX), reducing leukotriene production and thereby attenuating inflammatory cascades relevant to arthritis, asthma, and inflammatory bowel conditions.
**Immunomodulation**
Boswellic acid fractions suppress TNF-α production in lipopolysaccharide-stimulated monocytes, modulating innate immune responses and reducing cytokine-driven tissue damage.
**Antimicrobial Properties**
Essential oil components including α-pinene, α-thujene, and β-caryophyllene exhibit broad-spectrum antimicrobial activity against bacterial and fungal pathogens, supporting traditional use in wound healing and respiratory infections.
**Neuroprotective Potential**
Incensole and incensole acetate, volatile constituents of B. sacra essential oil, have demonstrated neuroprotective and anxiolytic properties in preclinical models, potentially modulating neuroinflammation and TRPV3 channels.
**Analgesic Support**
Via reduction of leukotriene B4 and prostaglandin synthesis through dual inhibition of 5-LOX and cyclooxygenase pathways, frankincense extracts may reduce pain signaling in chronic inflammatory states.
**Antineoplastic Potential**
Boswellic acids, particularly AKBA, have shown cytotoxic activity against several cancer cell lines in vitro by inducing apoptosis and inhibiting topoisomerase I and II, though human clinical evidence remains preliminary.
**Respiratory Health**
Traditional use for coughs, colds, and bronchial congestion is supported by the bronchodilatory and anti-leukotriene activity of boswellic acids, which may reduce airway inflammation relevant to asthma.
Origin & History
Natural habitat
Boswellia sacra is native to the arid, rocky hillsides of the Arabian Peninsula and the Horn of Africa, with primary cultivation concentrated in Oman, Yemen, and Somalia. The trees thrive in semi-arid environments with poor, rocky soils and minimal rainfall, often growing at elevations between 250–1,000 meters on limestone escarpments. Resin is harvested by tapping or wounding the bark, a traditional practice known as 'tapping,' which causes the tree to exude an oleo-gum resin that hardens into the characteristic pale-yellow to amber tears of frankincense.
“Frankincense from Boswellia sacra holds one of the longest documented histories of any botanical resin, with use traced back over 5,000 years across the Arabian Peninsula, the Horn of Africa, and the ancient Near East, where it served as a sacred incense in religious ceremonies of ancient Egypt, Mesopotamia, ancient Israel, and early Christianity. In Oman, where it is known as 'Luban Dhakar,' frankincense has been harvested and traded along the ancient Incense Route for millennia, graded by quality into categories such as Hojari (the finest grade), and used medicinally for colds, coughs, fevers, and wound healing. In Somali traditional medicine, frankincense resin is a cornerstone anti-inflammatory agent applied to joint pain, respiratory ailments, and skin conditions, often prepared as a decoction or consumed as raw resin tears. The tree and its resin feature prominently in Islamic tradition, referenced in classical Arabic medical texts by scholars such as Ibn Sina (Avicenna), who documented its use for digestive complaints, tumors, and pulmonary disorders in the Canon of Medicine.”Traditional Medicine
Scientific Research
The clinical evidence base for Boswellia sacra specifically is very limited, with the majority of human trials conducted on the closely related species Boswellia serrata; direct extrapolation should be made cautiously given differences in boswellic acid profiles between species. One referenced intervention using Boswellia serrata gum resin at 900 mg/day (300 mg three times daily for 6 weeks) demonstrated therapeutic effects in an inflammatory condition, though specific outcome measures and sample sizes were not fully reported in available literature. Preclinical studies on B. sacra extracts and isolated boswellic acids are more numerous, demonstrating 5-LOX inhibition, cytotoxicity in cancer cell lines, and antimicrobial activity in vitro, but these findings have not been systematically translated into powered human clinical trials for this specific species. Overall, the evidence for B. sacra per se remains at a preclinical and traditional-use level, and clinicians should treat efficacy claims derived from B. serrata trials as supportive but not definitive for B. sacra.
Preparation & Dosage
Traditional preparation
**Standardized Gum Resin Extract (Capsule/Tablet)**
900 mg/day (300 mg three times daily) of standardized extract; look for products standardized to 37
Based on Boswellia serrata proxy data, .5–65% total boswellic acids with specified AKBA content (≥10% AKBA preferred for anti-inflammatory use).
**Raw Oleo-Gum Resin (Traditional Chewing/Oral)**
1–3 g/day) used empirically
Traditionally consumed directly as hardened resin tears in Somali and Omani practice; no established standardized dose, typically small quantities (.
**Essential Oil (Aromatherapy/Topical)**
Obtained by hydro-distillation of resin (yielding 5–9% essential oil); used topically diluted in carrier oils (2–3% dilution) or inhaled; not suitable for internal use at undiluted concentrations.
**Alcohol Extract/Tincture**
Ethanol-soluble fraction concentrates lipophilic boswellic acids; preparation involves soaking resin in 70–95% ethanol to maximize terpenoid extraction; dose varies by standardization.
**High-Molecular-Weight Fraction (Fraction IV)**
Research preparations enriched in high-molecular-weight boswellic acids have been used in preclinical studies; not routinely available commercially.
**Timing Note**
Boswellic acids are lipophilic; bioavailability is enhanced when taken with a fatty meal; split dosing throughout the day is recommended to maintain plasma concentrations.
Nutritional Profile
Boswellia sacra oleo-gum resin is not a significant source of conventional macronutrients or micronutrients in supplemental doses. The resin is composed of approximately 60–70% alcohol-soluble resin fraction (rich in pentacyclic triterpenic acids including boswellic acids), 25–30% water-soluble polysaccharide gum (arabinogalactan-type polymers contributing to the mucilaginous quality), and 5–9% essential oil (dominated by esters at ~62.1%, including octyl acetate up to 39.3%; monoterpene hydrocarbons ~9.9% including α-pinene up to 10.9% and α-thujene up to 11.7%; sesquiterpenes ~1% including β-caryophyllene; and diterpenes ~42.5% including incensole and incensole acetate). AKBA and KBA (11-keto-β-boswellic acid) are the pharmacologically prioritized boswellic acids in standardized extracts, typically comprising the largest portion of the 37.5–65% total boswellic acid content found in commercial preparations. Bioavailability of boswellic acids is limited by their lipophilic nature and low aqueous solubility; formulation in lipid-based delivery systems or consumption with dietary fat significantly improves absorption.
How It Works
Mechanism of Action
AKBA (acetyl-11-keto-β-boswellic acid), the most pharmacologically potent boswellic acid in Boswellia sacra, non-competitively inhibits 5-lipoxygenase (5-LOX) at the enzyme's active site, blocking conversion of arachidonic acid to pro-inflammatory leukotrienes (LTB4, LTC4, LTD4) at effective concentrations of approximately 1–10 μM. Boswellic acids also inhibit human leukocyte elastase (HLE) and modulate nuclear factor-kappa B (NF-κB) signaling, reducing downstream transcription of inflammatory cytokines including TNF-α, IL-1β, and IL-6. Incensole acetate, a diterpene ester found in the essential oil fraction, activates TRPV3 (transient receptor potential vanilloid 3) channels and has been shown in animal models to reduce neuroinflammatory signaling and exert anxiolytic effects. Additionally, some boswellic acids inhibit complement activation and exhibit anticoagulant properties by interfering with thrombin activity, contributing to their broad immunomodulatory profile.
Clinical Evidence
No large-scale randomized controlled trials (RCTs) have been published specifically evaluating Boswellia sacra in human subjects for anti-inflammatory outcomes as of current literature. Boswellia serrata RCTs provide the closest proxy data; a 6-week intervention using 900 mg/day gum resin extract reported therapeutic benefit, though quantified effect sizes (e.g., pain VAS scores, cytokine reductions) were not fully disclosed in available search results. Preclinical evidence for B. sacra shows robust 5-LOX inhibition and antimicrobial activity, providing mechanistic plausibility for the traditional uses documented in Oman and Somalia. Confidence in clinical recommendations for B. sacra specifically is low-to-moderate, and well-designed RCTs with adequate sample sizes and standardized B. sacra extracts are needed before firm therapeutic claims can be established.
Safety & Interactions
Boswellia sacra has a historically low toxicity profile at traditional and supplemental doses, and no specific lethal dose or severe adverse event reports are established for this species in the peer-reviewed literature; mild gastrointestinal symptoms (nausea, diarrhea, stomach discomfort) have been reported anecdotally and in Boswellia serrata studies at higher doses. Due to its inhibition of 5-lipoxygenase and potential anticoagulant effects via thrombin interference, frankincense extracts may theoretically potentiate the effects of anticoagulant and antiplatelet medications (e.g., warfarin, aspirin, clopidogrel), and patients on these medications should consult a healthcare provider before use. Immunomodulatory properties suggest caution in individuals taking immunosuppressive drugs (e.g., cyclosporine, corticosteroids), as boswellic acids may alter immune modulation unpredictably. Pregnancy and lactation safety has not been established in controlled human studies; traditional use in pregnancy is not well-documented for therapeutic doses, and its use is not recommended during pregnancy or breastfeeding without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Boswellia sacraLuban DhakarOlibanumSacred FrankincenseLubaan (Somali)
Frequently Asked Questions
What is the difference between Boswellia sacra and Boswellia serrata?
Boswellia sacra (Sacred Frankincense) originates from Oman, Yemen, and the Horn of Africa, while Boswellia serrata is native to India and is the species most commonly used in standardized commercial supplements. Although both species contain boswellic acids including AKBA and KBA, their relative concentrations and essential oil compositions differ, with B. sacra containing higher levels of incensole and incensole acetate; most clinical trial evidence currently comes from B. serrata, so direct equivalence of dosing cannot be assumed.
How much frankincense should I take for inflammation?
There is no established clinical dose specifically for Boswellia sacra; based on the most relevant proxy data from Boswellia serrata trials, 900 mg/day of standardized gum resin extract (taken as 300 mg three times daily with meals) has been used therapeutically for inflammatory conditions. Look for products standardized to at least 37.5–65% total boswellic acids with AKBA content of 10% or greater for optimal anti-inflammatory potency, and always take with a fatty meal to improve bioavailability of the lipophilic boswellic acids.
Is frankincense safe to take daily as a supplement?
Boswellia sacra and related Boswellia species have a historically favorable safety profile at supplemental doses, with the primary reported adverse effects being mild gastrointestinal symptoms such as nausea or diarrhea. However, due to anticoagulant properties and 5-LOX inhibition, daily supplementation is not recommended without medical supervision for individuals on blood thinners (warfarin, aspirin), immunosuppressive drugs, or during pregnancy and lactation, as adequate human safety data for these populations is lacking.
What does AKBA in frankincense do in the body?
AKBA (acetyl-11-keto-β-boswellic acid) is the most pharmacologically potent boswellic acid in frankincense and acts primarily by non-competitively inhibiting the enzyme 5-lipoxygenase (5-LOX), which is responsible for converting arachidonic acid into pro-inflammatory leukotrienes (LTB4, LTC4, LTD4). At concentrations of 1–10 μM, AKBA also suppresses TNF-α production in immune cells and inhibits NF-κB transcriptional activity, collectively reducing multiple branches of the inflammatory cascade relevant to conditions such as arthritis, asthma, and inflammatory bowel disease.
How is frankincense traditionally prepared in Somali and Omani medicine?
In both Somali and Omani tradition, frankincense resin is harvested by making incisions in the bark of Boswellia sacra trees and allowing the exuded oleo-gum resin to harden into pale amber or white tears over several days, after which it is collected, graded by purity and color (with the premium Omani grade called Hojari being the most prized), and used either chewed directly as raw resin, burned as incense for respiratory conditions, or prepared as a decoction with water. In Oman it is known as Luban Dhakar and is used for colds, coughs, and fevers, while Somali traditional use emphasizes topical and oral applications for joint pain and wound healing.
Does frankincense interact with blood thinners or anticoagulant medications?
Frankincense may have mild anticoagulant properties due to its boswellic acids, so concurrent use with warfarin, aspirin, or other blood thinners should be discussed with a healthcare provider. While clinical evidence of serious interactions is limited, combining frankincense with anticoagulants could theoretically increase bleeding risk and warrants medical supervision. Always inform your doctor if you take frankincense alongside anticoagulant therapy.
Which form of frankincense supplement has the best absorption—resin, extract, or standardized powder?
Standardized extracts (typically standardized to 30% or higher boswellic acids) generally offer superior bioavailability compared to whole resin or unstandardized powders because they concentrate the active compounds and are easier to digest. Lipid-soluble boswellic acids are absorbed better when taken with fat-containing meals, which can enhance their therapeutic effect. Enteric-coated capsules may also improve delivery to the lower intestine, where anti-inflammatory effects may be most relevant for conditions like IBD.
Is frankincense safe for children or should it only be used by adults?
Limited safety data exists for frankincense in children, and pediatric dosing has not been well-established in clinical trials, so supplementation in children should only occur under qualified medical guidance. Traditional use suggests it has been safe in small amounts in children's formulas for respiratory health, but modern supplement safety standards require caution until more research is available. Consult a pediatrician or pediatric herbalist before giving frankincense to children.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w frankincense-boswellia-sacra curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
